Chrysos Corporation Limited (ASX:C79): How PhotonAssay Leasing Is Changing Its FY27 Pipeline

Aditi Sarkar

11 November 2026 04:49 PM AEDT

Chrysos Corporation Limited (ASX:C79): How PhotonAssay Leasing Is Changing Its FY27 Pipeline

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Chrysos reported FY26 Revenue of AUD 88.1 million, up 33% from FY25.
FY26 EBITDA increased 68% to AUD 27.2 million, with a 31% margin.
The company signed 24 new leases during FY26 and four after year-end.
Deployments and customer sample throughput are central to its FY27 growth plans.

Chrysos Corporation Limited (ASX:C79) provides mineral analysis technology for Mining companies and commercial laboratories. Its PhotonAssay system is used to analyse gold and other elements, while a leasing model places equipment at customer facilities and generates contractual income. In FY26, growth in installed technology and sample volumes supported higher revenue and earnings. The next operational question is how quickly contracted units become productive installations.

PhotonAssay Model and Customer Applications

PhotonAssay uses a different analytical process from traditional destructive fire-assay methods, providing data used in mining and laboratory workflows. Chrysos Corporation Limited (ASX:C79) leases units to customers rather than relying solely on outright equipment sales. Recurring contractual arrangements can provide an ongoing revenue base, although actual utilisation depends on the number of samples customers submit.

The company works with both laboratory operators and miners seeking direct access to assay capacity at production sites. Those installation settings have different logistical requirements, including site preparation, staff Training and equipment integration. Contract announcements therefore need to be distinguished from completed deployments and from the point at which a unit begins generating operating activity.

FY26 Revenue, Earnings and Throughput

For the year ended 30 June 2026, Chrysos Corporation Limited (ASX:C79) reported revenue of AUD 88.1 million, an increase of 33% from AUD 66.1 million in FY25. EBITDA rose 68% to AUD 27.2 million from AUD 16.1 million, taking the EBITDA Margin to 31% from 24%. EBITDA is an operating measure and does not equal net profit or cash flow.

The company processed approximately 11.3 million samples during FY26, an increase of 67%. It also reported five consecutive months from March 2026 in which monthly throughput exceeded one million samples. Higher volumes help explain the Operating Leverage in the results, but sample Demand can fluctuate with customers’ exploration budgets and mine activity.

Contracted Units and Deployment Schedule

Chrysos signed 24 new unit leases in FY26, followed by four additional agreements after the period ended, taking the contracted fleet to 87 units. The company reported seven new deployments during FY26, with another six units in deployment at the results date. Contracted fleet size is not the same as the number installed, commissioned or fully utilised.

Chrysos Corporation Limited (ASX:C79) has been expanding direct-to-mine relationships alongside its established commercial laboratory customers. The company’s next-generation XN technology is another product development step. New systems must perform reliably after commissioning, and the time between contract signature and productive use can materially affect the pattern of recognised revenue.

FY27 Outlook and Operational Constraints

Chrysos Corporation Limited (ASX:C79) provided FY27 guidance for revenue of AUD 108 million to AUD 118 million and EBITDA of AUD 35 million to AUD 42 million. These figures are company forecasts, not achieved results. Delivery depends on the build-out of contracted units, installation schedules, effective servicing and sample volumes at operating sites.

The mining cycle creates a further exposure: reduced exploration programmes or slower customer activity could affect sample throughput even with equipment in place. Expansion across jurisdictions also adds logistical and working-capital demands. Tracking deployed units together with utilised capacity will therefore be more informative than interpreting Lease signings alone as realised earnings.

Key Insights

Chrysos Corporation Limited (ASX:C79) grew FY26 revenue and EBITDA through PhotonAssay adoption and heavier sample throughput. The contracted pipeline supports its FY27 plans, but commissioning schedules, equipment performance and customer activity remain relevant uncertainties.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.